Alkermes (ALKS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $41.22, +2.79% vs the prior close of $40.10.
- Volume 3.26M shares, 1.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ALKS rises 2.8% to $41.22. Closed at $41.22, +2.79% vs the prior close of $40.10. Day range $39.71–$41.57, opened at $40.20.
ALKS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ALKS rises 2.8% to $41.22
- Closed at $41.22, +2.79% vs the prior close of $40.10. Day range $39.71–$41.57, opened at $40.20.
- Volume was 3.26M shares, 1.8x its 50-day average of 1.86M.
- Price is -8.6% vs its 50-day average ($45.08) and +3.8% vs its 200-day average ($39.72).
- 52-week range $27.00–$55.67; today's close sits at 50% of that range, 26.0% below the 52-week high.
Oct 15, 2026 — ALKS rises 2.6% to $40.10
- Closed at $40.10, +2.61% vs the prior close of $39.08. Day range $39.42–$40.74, opened at $39.74.
- Volume was 1.98M shares, 1.1x its 50-day average of 1.85M.
- Price is -11.3% vs its 50-day average ($45.22) and +1.1% vs its 200-day average ($39.65).
- 52-week range $27.00–$55.67; today's close sits at 46% of that range, 28.0% below the 52-week high.
Oct 14, 2026 — ALKS dips 1.6% to $39.08, a 3-month low, 3 down days in a row
- Closed at $39.08, -1.64% vs the prior close of $39.73. Day range $38.98–$40.65, opened at $39.59.
- Volume was 1.55M shares, 0.8x its 50-day average of 1.85M.
- Price is -13.9% vs its 50-day average ($45.41) and -1.3% vs its 200-day average ($39.59).
- 52-week range $27.00–$55.67; today's close sits at 42% of that range, 29.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ALKS dips 1.3% to $39.73, a 3-month low
- Closed at $39.73, -1.32% vs the prior close of $40.26. Day range $39.67–$40.35, opened at $40.26.
- Volume was 1.07M shares, 0.6x its 50-day average of 1.87M — lighter than usual.
- Price is -12.9% vs its 50-day average ($45.62) and +0.5% vs its 200-day average ($39.53).
- 52-week range $27.00–$55.67; today's close sits at 44% of that range, 28.6% below the 52-week high.
Oct 12, 2026 — ALKS dips 0.9% to $40.26
- Closed at $40.26, -0.86% vs the prior close of $40.61. Day range $40.00–$40.87, opened at $40.67.
- Volume was 2.24M shares, 1.2x its 50-day average of 1.86M.
- Price is -12.1% vs its 50-day average ($45.82) and +2.0% vs its 200-day average ($39.48).
- 52-week range $27.00–$55.67; today's close sits at 46% of that range, 27.7% below the 52-week high.
Oct 9, 2026 — ALKS rises 1.2% to $40.61
- Closed at $40.61, +1.25% vs the prior close of $40.11. Day range $39.99–$40.87, opened at $40.18.
- Volume was 1.63M shares, 0.9x its 50-day average of 1.87M.
- Price is -11.7% vs its 50-day average ($45.99) and +3.0% vs its 200-day average ($39.42).
- 52-week range $27.00–$55.67; today's close sits at 47% of that range, 27.1% below the 52-week high.
Oct 8, 2026 — ALKS slides 3.2% to $40.11, a 3-month low, 3 down days in a row
- Closed at $40.11, -3.23% vs the prior close of $41.45. Day range $39.11–$41.26, opened at $41.10.
- Volume was 3.25M shares, 1.7x its 50-day average of 1.89M.
- Price is -13.1% vs its 50-day average ($46.18) and +1.9% vs its 200-day average ($39.36).
- 52-week range $27.00–$55.67; today's close sits at 46% of that range, 28.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ALKS dips 0.5% to $41.45
- Closed at $41.45, -0.48% vs the prior close of $41.65. Day range $41.17–$42.06, opened at $41.28.
- Volume was 1.82M shares, 1.0x its 50-day average of 1.91M.
- Price is -10.6% vs its 50-day average ($46.35) and +5.5% vs its 200-day average ($39.30).
- 52-week range $27.00–$55.67; today's close sits at 50% of that range, 25.5% below the 52-week high.
Oct 6, 2026 — ALKS dips 2.6% to $41.65
- Closed at $41.65, -2.60% vs the prior close of $42.76. Day range $41.24–$42.71, opened at $42.64.
- Volume was 1.55M shares, 0.8x its 50-day average of 1.91M.
- Price is -10.5% vs its 50-day average ($46.53) and +6.2% vs its 200-day average ($39.23).
- 52-week range $27.00–$55.67; today's close sits at 51% of that range, 25.2% below the 52-week high.
Oct 5, 2026 — ALKS rises 2.4% to $42.76, 3 up days in a row
- Closed at $42.76, +2.42% vs the prior close of $41.75. Day range $41.67–$43.22, opened at $42.07.
- Volume was 3.13M shares, 1.7x its 50-day average of 1.87M.
- Price is -8.5% vs its 50-day average ($46.75) and +9.2% vs its 200-day average ($39.17).
- 52-week range $27.00–$55.67; today's close sits at 55% of that range, 23.2% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — ALKS rises 3.0% to $41.75
- Closed at $41.75, +2.98% vs the prior close of $40.54. Day range $40.32–$41.96, opened at $41.03.
- Volume was 2.42M shares, 1.3x its 50-day average of 1.85M.
- Price is -11.1% vs its 50-day average ($46.95) and +6.8% vs its 200-day average ($39.09).
- 52-week range $27.00–$55.67; today's close sits at 51% of that range, 25.0% below the 52-week high.
ALKS latest news & SEC filings
Every SEC filing by or about ALKS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Reed Joshua converted options/RSUs into 9,164 shares on Oct 8, 2026; now holds 9,164
- Reed Joshua had withheld for taxes 4,069 shares at $40.11 (≈$163.21K) on Oct 8, 2026; now holds 5,095
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gaffin David Joseph sold 2,034 shares at $41.03 (≈$83.46K) on Oct 2, 2026; now holds 221,388
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gaffin David Joseph sold 2,034 shares at $48.01 (≈$97.65K) on Sep 3, 2026
- Gaffin David Joseph sold 2,034 shares at $48.01 (≈$97.65K) on Sep 3, 2026
- Gaffin David Joseph sold 2,034 shares at $48.01 (≈$97.65K) on Sep 3, 2026
- Gaffin David Joseph sold 2,034 shares at $48.01 (≈$97.65K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 3, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 28, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 28, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $496.01M (prior year $390.66M) (+27.0% vs Jun 30, 2025)
- Net income: $501.00K (prior year $87.10M) (-99.4% vs Jun 30, 2025)
- Diluted EPS: $0.00 (prior year $0.52) (-100.0% vs Jun 30, 2025)
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
Things to know before you trade ALKS
- Last results release: Jul 28, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 25, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 27, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.80% (largest 3.2%).
- Liquidity: about 2.40M shares (≈$99.00M) trade per day on average.
- 52-week position: $41.22 vs a range of $27.00–$55.67 (50% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: David Joseph Gaffin sold 2,034 shares on Sep 3, 2026.
- Latest filings: 8-K Sep 21, 2026; 8-K Sep 16, 2026; 8-K Aug 12, 2026.
- Share count: 167.76M shares outstanding (Jul 23, 2026), +1.6% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ALKS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 40.20 | 41.57 | 39.71 | 41.22 | 3.26M |
| Oct 15, 2026 | 39.74 | 40.74 | 39.42 | 40.10 | 1.98M |
| Oct 14, 2026 | 39.59 | 40.65 | 38.98 | 39.08 | 1.55M |
| Oct 13, 2026 | 40.26 | 40.35 | 39.67 | 39.73 | 1.07M |
| Oct 12, 2026 | 40.67 | 40.87 | 40.00 | 40.26 | 2.24M |
| Oct 9, 2026 | 40.18 | 40.87 | 39.99 | 40.61 | 1.63M |
| Oct 8, 2026 | 41.10 | 41.26 | 39.11 | 40.11 | 3.25M |
| Oct 7, 2026 | 41.28 | 42.06 | 41.17 | 41.45 | 1.82M |
| Oct 6, 2026 | 42.64 | 42.71 | 41.24 | 41.65 | 1.55M |
| Oct 5, 2026 | 42.07 | 43.22 | 41.67 | 42.76 | 3.13M |
| Oct 2, 2026 | 41.03 | 41.96 | 40.32 | 41.75 | 2.42M |
| Oct 1, 2026 | 40.00 | 41.41 | 39.99 | 40.54 | 2.63M |
| Sep 30, 2026 | 40.94 | 40.94 | 39.92 | 40.52 | 2.53M |
| Sep 29, 2026 | 39.84 | 40.90 | 39.84 | 40.80 | 2.69M |
| Sep 28, 2026 | 40.71 | 40.97 | 40.04 | 40.15 | 2.36M |
| Sep 25, 2026 | 40.94 | 41.12 | 40.49 | 40.85 | 2.59M |
| Sep 24, 2026 | 42.55 | 42.55 | 40.59 | 40.79 | 2.84M |
| Sep 23, 2026 | 43.20 | 43.62 | 41.23 | 42.13 | 2.48M |
| Sep 22, 2026 | 44.39 | 44.53 | 43.08 | 43.29 | 2.31M |
| Sep 21, 2026 | 44.27 | 44.79 | 43.11 | 44.18 | 3.73M |
About Alkermes
Alkermes (ALKS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in DUBLIN 4, Ireland. Fiscal year ends December 31. SEC CIK 1520262.
ALKS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Shane Cooke | Director | May 22, 2026 |
| Richard Gaynor | Director | May 22, 2026 |
| Blair Curtis Jackson | President & CEO, Alkermes plc | Aug 7, 2026 |
| Cato T Laurencin | Director | May 22, 2026 |
| Nancy Lurker | Director | May 22, 2026 |
| Brian P Mckeon | Director | May 22, 2026 |
| Richard F Pops | Director and CEO, Alkermes plc | Mar 4, 2026 |
| Anne Clem Whitaker | Director | Sep 18, 2026 |
| Frank Anders Wilson | Director | May 22, 2026 |
| Christopher I Wright | Director | Jun 12, 2026 |
| Nancy Lynn Md Snyderman | Director | Aug 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sep 3, 2026 |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | Sep 1, 2026 |
| Blair Curtis Jackson | President & CEO, Alkermes plc | Aug 7, 2026 |
| Christian Todd Nichols | SVP, Chief Commercial Officer | Aug 17, 2026 |
| Richard F Pops | Director and CEO, Alkermes plc | Mar 4, 2026 |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | May 29, 2026 |
| Joshua Reed | SVP, Chief Financial Officer | Mar 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | David Joseph Gaffin | Sale | 2,034 | $48.01 |
| Sep 3, 2026 | David Joseph Gaffin | Sale | 2,034 | $48.01 |
| Sep 3, 2026 | David Joseph Gaffin | Sale | 2,034 | $48.01 |
| Sep 3, 2026 | David Joseph Gaffin | Sale | 2,034 | $48.01 |
| Sep 1, 2026 | Craig C. Hopkinson | Sale | 9,000 | $46.99 |
| Sep 1, 2026 | Craig C. Hopkinson | Sale | 9,000 | $46.99 |
| Sep 1, 2026 | Craig C. Hopkinson | Sale | 9,000 | $46.99 |
| Sep 1, 2026 | Craig C. Hopkinson | Sale | 9,000 | $46.99 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 664 | $49.65 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 6,912 | $49.19 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 664 | $49.65 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 6,912 | $49.19 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 664 | $49.65 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 6,912 | $49.19 |
| Aug 17, 2026 | Christian Todd Nichols | Sale | 664 | $49.65 |
ALKS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.48B | $241.66M | 1.43 | $520.75M |
| Dec 31, 2024 | $1.56B | $367.07M | 2.17 | $439.12M |
| Dec 31, 2023 | $1.66B | $355.76M | 2.10 | $401.35M |
| Dec 31, 2022 | $1.11B | $-158.27M | -0.97 | $21.04M |
| Dec 31, 2021 | $1.17B | $-48.17M | -0.29 | $101.72M |
Latest balance sheet: total assets $4.39B, total liabilities $2.58B, cash $511.53M (as of Jun 30, 2026).
ALKS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 28, 2026 | 8-K Item 2.02 (results) | $50.50 |
| May 5, 2026 | 8-K Item 2.02 (results) | $36.25 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $31.04 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $29.62 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $31.00 |
| Oct 22, 2025 | 8-K Item 2.02 (results) | $31.09 |
| Jul 29, 2025 | 8-K Item 2.02 (results) | $27.00 |
| May 1, 2025 | 8-K Item 2.02 (results) | $30.58 |
| Feb 12, 2025 | 8-K Item 2.02 (results) | $33.50 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $28.35 |
| Oct 24, 2024 | 8-K Item 2.02 (results) | $26.85 |
| Jul 24, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ALKS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.